Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Qiagen NV (QGEN)
NYSE:QGEN
Holding QGEN?
Track your performance easily
QGEN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$38.66 - $47.44
Previous Close$43.95
Volume1.60M
Average Volume (3M)1.17M
Market Cap
$9.68B
Enterprise Value$10.16B
Total Cash (Recent Filing)$1.06B
Total Debt (Recent Filing)$1.53B
Price to Earnings (P/E)140.1
Beta0.81
Next Earnings
Feb 11, 2025EPS Estimate
$0.6Last Dividend Ex-Date
Jan 30, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)0.31
Shares Outstanding228,202,755
10 Day Avg. Volume858,518
30 Day Avg. Volume1,172,935
Standard Deviation0.09
R-Squared0.06
Alpha0.00391
Financial Highlights & Ratios
Price to Book (P/B)2.63
Price to Sales (P/S)5.10
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.01
Enterprise Value/Gross Profit8.23
Enterprise Value/Ebitda29.71
Forecast
1Y Price Target
$49.00Price Target Upside11.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Qiagen News
PremiumCompany Announcements
Qiagen’s Financial Growth and Rising Debt in Q3 2024
PremiumCompany Announcements
Qiagen’s Q3 2024 Results Exceed Expectations, Boost OutlookBulls Say, Bears Say
Bulls Say
Market Share GrowthQGEN expects their easy-to-use and more specific blood-based offering to continue to gain market share despite new entrants.
Product DemandQuantiFERON showed strong demand driven by continued skin testing conversion, and QIAstat-Dx saw double-digit consumables growth.
Strategic InvestmentsQGEN looks to return $1bn back to shareholders during this time, and called out M&A specifically - noting that M&A needs to be synergistic and targeted.
Bears Say
Customer CautionLingering customer caution on capital equipment is causing pressure on QGEN's sales.
Market ConditionsQGEN is facing ongoing challenges in China, with difficult market conditions expected to continue.
Revenue GuidanceThe decision to discontinue NeuMoDx has led to a modest reduction in QGEN's revenue guidance.
---
Ownership Overview
0.44% Insiders
18.22% Mutual Funds
0.69% Other Institutional Investors
66.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
QGEN FAQ
What was Qiagen NV’s price range in the past 12 months?
Qiagen NV lowest stock price was $38.66 and its highest was $47.44 in the past 12 months.
What is Qiagen NV’s market cap?
Currently, no data Available
When is Qiagen NV’s upcoming earnings report date?
Qiagen NV’s upcoming earnings report date is Feb 11, 2025 which is in 93 days.
How were Qiagen NV’s earnings last quarter?
Qiagen NV released its earnings results on Nov 06, 2024. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.543 by $0.027.
Is Qiagen NV overvalued?
According to Wall Street analysts Qiagen NV’s price is currently Undervalued.
Does Qiagen NV pay dividends?
Qiagen NV pays a Notavailable dividend of $1.28 which represents an annual dividend yield of N/A. See more information on Qiagen NV dividends here
What is Qiagen NV’s EPS estimate?
Qiagen NV’s EPS estimate is $0.6.
How many shares outstanding does Qiagen NV have?
Qiagen NV has 221,847,000 shares outstanding.
What happened to Qiagen NV’s price movement after its last earnings report?
Qiagen NV reported an EPS of $0.57 in its last earnings report, beating expectations of $0.543. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Qiagen NV?
Among the largest hedge funds holding Qiagen NV’s share is Woodline Partners LP. It holds Qiagen NV’s shares valued at 15M.
---
Qiagen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$49.00 (11.69% Upside)
$49.00 (11.69% Upside)
Blogger Sentiment
Bullish
QGEN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 30.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 3.7%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.54%
12-Months-Change
Fundamentals
Return on Equity
2.07%
Trailing 12-Months
Asset Growth
-12.02%
Trailing 12-Months
Company Description
Qiagen NV
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
---
QGEN Company Deck
---
QGEN Earnings Call
Q2 2024
0:00 / 0:00
---
QGEN Stock 12 Month Forecast
Average Price Target
$49.00
▲(11.69% Upside)
Technical Analysis
Best Analysts Covering QGEN
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
+1.83%
reiterated a buy rating 3 months ago
Copying Aisyah Noor's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +1.83% per trade.
---